人组织激肽释放酶在肝癌中的研究进展  

Research progress of human tissue kallikrein in hepatocellular carcinoma

作　　者：程大伟(综述) 郑军(审校)[1] CHENG Da-wei;ZHENG Jun(Department of Hepatobiliary and Pancreatic Surgery,the First Clinical College of China Three Gorges University(Yichang Central People's Hospital)&Institute of Hepatobiliary and Pancreatic Surgery,China Three Gorges University,Yichang 443003,Hubei,CHINA)

机构地区：[1]三峡大学第一临床医学院(宜昌市中心人民医院)肝胆胰外科三峡大学肝胆胰外科研究所,湖北宜昌443003

出　　处：《海南医学》2023年第11期1661-1666,共6页Hainan Medical Journal

基　　金：湖北陈孝平科技发展基金会资助项目(编号:CXPJJH118000017-02-07)。

摘　　要：肝癌是一种高度恶性的消化系统肿瘤,因其早期无典型症状,不易引起人们重视,一旦确诊已是进展期或晚期。人组织激肽释放酶(KLKs)是丝氨酸蛋白酶家族中一种具有胰蛋白酶或胰凝乳蛋白酶性质的蛋白水解酶亚群,与恶性肿瘤的增殖、侵袭和转移密切相关,可以作为一些恶性肿瘤的生物学标志物应用于疾病的早期筛查、明确诊断、个性化治疗以及预后评估等临床实践中。本文综述了KLKs基因及其在肝癌中的表达调控、作用机制、化疗敏感性及预后价值。Liver cancer is a highly malignant tumor of the digestive system.Because there are no typical symp-toms in early stage,it is not easy to attract people's attention,and is of advanced or late stage when diagosed.Human tis-sue kallikrein-related peptidases(KLKs)is a subgroup of proteolytic enzymes with trypsin or chymotrypsin properties in the serine protease family,which closely related to the proliferation,invasion and metastasis of malignant tumors,and can be used as biological makers of some malignant tumors in clinical practice,such as early screening of disease,defi-nite diagnosis,personalized treatment and prognosis assessment.This article reviews the KLKs gene and its expression regulation,mechanism of action,sensitivity to chemotherapy and prognostic value in hepatocellular carcinoma.

关 键 词：组织激肽释放酶 肝癌 生物学标志物 研究进展 

分 类 号：R735.7[医药卫生—肿瘤]